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Objectives 
We investigated potential interactions between BMI and genotypes of human leukocyte 
antigen (HLA), TCF7L2-rs7903146 and FTO-rs9939609 in relation to the risk of latent 
autoimmune diabetes in adults (LADA) and type 2 diabetes. 
Methods  
We pooled data from two population-based studies; a Swedish study with incident cases of 
LADA (GADA positive, n=394) and type 2 diabetes (GADA negative, n=1,290) and matched 
non-diabetic controls (n=2,656) and a prospective Norwegian study, including incident cases 
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of LADA (n=131) and type 2 diabetes (n=1,901) and 886,120 person-years of follow-up. 
Analyses were adjusted for age, gender, physical activity and smoking. Interaction between 
overweight (BMI ≥25 kg/m2) and HLA/ TCF7L2/ FTO high-risk genotypes was assessed by 
attributable proportion due to interaction (AP).  
Results 
The combination of overweight and high-risk genotypes of HLA, TCF7L2 and FTO was 
associated with a RRpooled of 7.59 (Confidence interval 5.27-10.93), 2.65 (1.97-3.56) and 2.21 
(1.60-3.07), respectively, for LADA, compared to normal weight individuals with 
low/intermediate genetic risk. There was a significant interaction between overweight and 
HLA (AP=0.29, 0.10-0.47), TCF7L2 (AP=0.31, 0.09-0.52) and FTO (AP=0.38, 0.15-0.61). 
The highest risk of LADA was seen in overweight individuals homozygous for the DR4 
genotype (RR=26.76, 15.42-46.43, AP=0.58, 0.32-0.83 [Swedish data]). Overweight and 
TCF7L2 also significantly interacted in relation to type 2 diabetes (AP=0.26, 0.19-0.33), 
however no interaction was observed with high-risk genotypes of HLA or FTO.  
Conclusions 
These results indicate that overweight interacts with HLA high-risk genotypes but also with 
genes associated with type 2 diabetes in the promotion of LADA.  
In this large study we found that overweight significantly interacts with HLA high-risk genotypes, and 
with variants of TCF7L2 and FTO in relation to the risk of Latent Autoimmune Diabetes in Adults. . 
Introduction 
Overweight is by far the most influential environmental risk factor for type 2 diabetes (1). 
Accumulating evidence indicates that excessive weight may also promote autoimmune 
diabetes in both children (2) and adults (3). We recently showed that obesity increased the 
risk of latent autoimmune diabetes in adults (LADA) 3-6 fold and that the risk was 
particularly high in those with a combination of overweight and family history of diabetes 
(4). This suggests that the influence of overweight on the development of LADA may be 
modified by genetic susceptibility. 
LADA is described as a hybrid form of diabetes with a pathogenesis that includes 
autoimmune destruction of the beta-cells as well as insulin resistance (5). Similar to type 1 
diabetes, the genetic susceptibility to LADA is strongly linked to the human leucocyte 
antigen (HLA) gene complex, in particular DRB1 and DQB1 with the HLA-DRB1*04-
DQB1*0302 and HLA-DRB1*0301-DQB1*0201 haplotypes conferring the highest risk (6-
8). LADA has also been associated with variants increasing the risk of type 2 diabetes e.g. in 
the transcription factor 7-like 2 (TCF7L2) gene in some (9-11) but not in all (12,13) studies, 
including a recent GWAS (8), as well as with variants in the fat mass and obesity-associated 
FTO gene in the Norwegian HUNT Study (12).   
In order to clarify the influence of overweight on the development of LADA we 
investigated the risk of LADA compared to type 2 diabetes in relation to interaction between 
overweight and a) HLA high-risk genotypes and b) risk variants in the TCF7L2 and FTO loci. 
For this purpose, we used data from two large population-based Scandinavian studies with 
incident cases of LADA and type 2 diabetes.  
Materials and Methods 
The ESTRID Study 
Study population: ESTRID (Epidemiological study of risk factors for LADA and type 2 
diabetes; https://ki.se/imm/estrid) is a population-based case-control study described in detail 
previously (14). It is a sub-study of ANDIS (All New Diabetics in Scania; 
http://andis.ludc.med.lu.se), a large scale diabetes register and biobank aiming at recruiting 
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and characterizing all new cases of diabetes in the county of Scania in southern Sweden by 
means of clinical and genetic information (15). To ESTRID we have invited all incident cases 
of LADA registered in ANDIS since 2010 together with a random sample of incident cases of 
type 2 diabetes. Non-diabetic control subjects within ESTRID provide questionnaire 
information but no laboratory data (n=1938). We included data for non-diabetic control 
subjects from the EIRA-study (Epidemiological Investigation of Rheumatoid Arthritis; 
https://www.eirasweden.se)(16), an ongoing case-control study based on similar 
methodology and questionnaire but also including biobank data. These control subjects are 
randomly selected from the Swedish population register and matched to the cases by age and 
gender. Analyses presented in this paper are based on all cases of LADA (n=394) and type 2 
diabetes (n=1,290) participating in ESTRID between 2010 and July 2017 and controls 
(inclusion criteria were age ≥35 years and free of diabetes and rheumatoid arthritis, n=2,656), 
recruited in EIRA between 1996 and 2014, with information on BMI, all covariates and at 
least one of the genotypes of interest. All participants provided written informed consent and 
the study was approved by the Regional Ethical Review Board in Stockholm. 
In ANDIS, blood samples were taken at diagnosis and diabetes classification was based 
on age at diagnosis, glutamic acid decarboxylase autoantibodies (GADA) and fasting C-
peptide. Analyses of GADA were performed using ELISA (enzyme-linked immunosorbent 
assay; RSR Limited, Cardiff, UK). Values above 250 IU/ml are censored at 250 IU/ml and 
the assay has a sensitivity of 84% and specificity of 98% for a cut-off level of 10.7 IU/ml 
(17). C-peptide was determined using the Cobas e 601 analyzer (Roche Diagnostics, 
Mannheim, Germany) or IMMULITE 2000 (Siemens Healthcare Diagnostics Product Ldt., 
Llanberies, UK). LADA was defined as age at diabetes diagnosis ≥35 years, GADA 
positivity (≥10 IU/ml), and C-peptide level above the lower limit of the normal range; ≥0.2 
nmol/l (IMMULITE) or ≥0.3 nmol/l (Cobas). The LADA definition is in line with previously 
used criteria (5)  with the exception of C-peptide which has been suggested to be a more 
objective marker of remaining insulin production than the most commonly adopted insulin 
criterion i.e. free of insulin treatment 3-12 months after diagnosis (18). Criteria for type 2 
diabetes were age ≥35 years, GADA negativity (<10 IU/ml) and C-peptide >0.6 nmol/l 
(IMMULITE) or >0.72 nmol/l (Cobas). 
DNA samples from the ANDIS biobank were analyzed at the Lund University Diabetes 
Centre using iPLEX Gold technology (Sequenom Laboratories, San Diego, CA, USA). 
Imputation for missing genotypes was performed on a subset using Infinium CoreExome v1.1 
(Illumina, San Diego, CA,USA), based on the Haplotype Reference Consortium 
(http://www.haplotype-reference-consortium.org/; version r1.1 2016) reference panel. DNA 
samples from the EIRA biobank were analyzed with the Illumina Global Screening array or 
an Infinium Illumina 300K immunochip custom array (Illumina, San Diego, CA, USA). For 
the present study we used SNPs in the HLA region (rs3104413, rs2854275, rs9273363), the 
TCF7L2 gene (rs7903146) and the FTO gene (rs9939609). The HLA DRB1 and DQB1 
genotypes associated with high (DR4/4, DR3/3, DR3/4, DR3/4-DQ8, DR4/4-DQ8, DR4/X-
DQ8) or low/intermediate (DR4/X, DR3/X, DRX/X, DR4-DQ7) risk for type 1 diabetes were 
imputed from the SNP genotypes based on a previously described methodology validated 
with an overall accuracy of 99.3% (19).  
Information on BMI and covariates was collected by questionnaire for all cases and 
controls at inclusion (median 5 months after diagnosis for cases). Self-reported BMI was 
calculated as weight in kilograms divided by the square of height in meters, which shows 
high correlation with BMI based on clinical measurements from time of diagnosis (patients 
only) (r=0.92, p <0,0001 [mean and standard deviation; 30.4 (5.5) for self-reports vs. 30.8 
(5.6) for medical records, n=1622 (LADA n=376, type 2 diabetes n=1246)]). Detailed 
information on smoking history was used to categorize individuals as never, former or current 
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smokers. Physical activity was assessed with validated questions on leisure time activity (20) 
during the preceding year and categorized as sedentary, low, moderate or high activity. 
The HUNT Study 
The HUNT Study (21) consists of three health surveys (HUNT1, 1984-1986; HUNT2, 1995-
97; HUNT3, 2006-08) conducted in the Norwegian county of Nord-Trøndelag. The surveys 
target all residents ≥ 20 years and include detailed questionnaires on lifestyle and health, 
clinical examinations, anthropometrical measurements and blood sampling. For the present 
study, the analytical sample comprised all individuals free of diabetes at baseline, who 
participated in at least two surveys with baseline information on BMI, age, gender, physical 
activity and smoking as well as genotypes for HLA, TCF7L2 or FTO (n=48,599). 
Participants provided informed consent and the study was approved by the Norwegian Data 
Protection Authority and the Regional Committee for Medical and  
Health Research Ethics. 
Incident cases of diabetes were identified by self-report at HUNT2 or HUNT3 (correlation 
with diagnosis from medical records was high; r=0.92 (22). At screening all cases with self-
reported diabetes were invited to a follow-up examination where fasting blood samples were 
collected (median 4 years after diagnosis). Serum C-peptide measurements (not from time of 
diagnosis) were analysed by RIA (Diagnostic Systems Laboratories, Webster, TX, USA). 
Serum GADA measurements were performed by immunoprecipitation radioligand assay 
using translation labelled 3H-GAD65 (Novo Nordisk, Bagsværd, Denmark) and expressed as 
an index value relative to standard serum. In the IASP 2003 workshop the assay had a 
sensitivity of 0.64 and a specificity of 1.00 at the cut-off antibody index ≥0.08 used in the 
present study, which equals ≥43 IU/ml according to the WHO standard (23). LADA (n=131) 
was defined as age ≥35 years at diagnosis and GADA positivity, and type 2 diabetes 
(n=1,901) as age ≥35 years and GADA negativity. With these criteria, the LADA group will 
inevitably include also type 1 diabetes patients with adult onset. However, the proportion is 
likely to be small; among those with information on treatment (87.8%, n=105), the majority 
(81.7%) of the GADA positive patients with adult onset reported that they were without 
insulin treatment during the first year after diagnosis.  
DNA was extracted for all participants in HUNT2 and HUNT3 with available blood 
samples and genotyped for SNPs associated with HLA-DRB1 and HLA-DQB1, TCF7L2 
(rs7903146) and FTO (rs9939609) at the NTNU Genomic Core Facility, Trondheim by 
HumanCoreExome, Illumina Inc (San Francisco, CA, USA https://www.ntnu.no/hunt/gwas-
data). Imputation was performed using Minimac3 (v2.0.1, 
http://genome.sph.umich.edu/wiki/Minimac3) and a customized Haplotype Reference 
consortium release 1.1 (HRC v1.1). Three SNPs, tagging the HLA region were available in 
HUNT (rs2854275, rs9273363, rs9272346) out of which two (rs2854275 and rs9273363) 
were the same as in ESTRID. Participants with at least one of the risk genotypes; rs2854275 
(TT/TG), rs9273363 (AA) or rs9272346 (AA) were considered to have a HLA high-risk 
genotype. Selection of the included SNPs was based on publicly available results from 
LADA and type 1 diabetes studies (13,15,19) and the availability in our data.  
Weight and height from the baseline clinical examination were used to calculate BMI as 
kg/m2. Baseline questionnaire information was used to classify individuals into never, former 
or current smokers and to determine level of leisure time physical activity as sedentary, low, 
moderate or high activity.  
In both cohorts, fasting C-peptide and glucose were used to calculate homeostasis model 
assessment indices (24) of insulin resistance (HOMA-IR) and beta-cell function (HOMA-B). 
Statistical analyses 
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Differences in baseline characteristics were assessed with two-sided p-values, calculated with 
Student’s t-test for means (SD), Kruskal–Wallis for medians (interquartile range [IQR]) of 
non-normally distributed variables (normality was assessed by visual evaluation of the 
distribution), and χ2 for proportions. The association between genotype and LADA/type 2 
diabetes was assessed by odds ratios (ORs) with 95% confidence intervals (CIs) derived by 
conditional logistic regression for case–control data and hazard ratios (HRs) with CIs 
calculated by proportional Cox regression for prospective data, modelled with age as the 
underlying time scale. For convenience, we will use the term relative risk (RR) to describe 
the effect estimates in present study. In HUNT, person-years were calculated from age at 
baseline until age at onset of diabetes, death or age at follow-up (in HUNT2 or HUNT3), 
whichever came first. Time-dependent variables were used, meaning that for individuals 
participating in both HUNT1 and HUNT2, information on exposure and covariates was 
updated at the second time of participation. All analyses were adjusted for age and gender 
(conditional variables in the case-control study) and where specified, additionally for physical 
activity and smoking. Additional adjustment for education (primary school, upper secondary 
school or university) and alcohol consumption (abstainers, low, moderate or high consumers) 
did not influence the effect estimates (<10% change) and these variables were not included in 
the final model. Study-specific RRs were calculated and pooled using the inverse variance 
method (25). Both TCF7L2-rs7903146 (TT/TC vs. CC) and FTO-rs9939609 (AA/AT vs. TT) 
were analyzed with a dominant model. In the specific HLA DR-DQ genotype analyses only 
Swedish data were used because we did not have SNPs tagging the DR4 genotype in HUNT. 
Patients with LADA were stratified by median GADA level (206 IU/ml [ESTRID] and 151 
IU/ml [HUNT]), from here on referred to as LADAhigh and LADAlow. In HUNT, we also 
performed sensitivity analyses based on a stricter definition of LADA (i.e. no insulin 
treatment during the first year of diagnosis). Interaction between overweight and genotype, 
defined as departure from additivity of effects (super-additive associations), was assessed 
with attributable proportion (AP) due to interaction using the formula: ([RR11 – RR10 – RR01 
+ 1] /RR11) (26) where RR11 is the risk among those with overweight and the high-risk 
genotype, RR10 those with overweight and the low/intermediate risk genotype and RR01 those 
with normal weight and the high-risk genotype). The reference group was normal weight 
individuals without the genetic risk variant of interest. In an additional interaction analysis we 
raised the cutoff for BMI to ≥30 kg/m2 to assess the impact of the genotypes in obese vs. 
non-obese individuals. All statistical calculations were performed with Statistical Analysis 
Software (SAS) 9.4 (SAS Institute, Cary, NC, USA). 
Results 
Characteristics 
In ESTRID (Table 1) individuals with LADA were leaner and younger, had lower insulin 
secretion (C-peptide and HOMA-B) but were less insulin resistant (HOMA-IR) than those 
with type 2 diabetes. The control subjects were younger and more often females than the 
patients, this difference was handled by post-matching in the subsequent analyses. In HUNT, 
patients with LADA and type 2 diabetes differed less than in ESTRID but the LADA patients 
had lower levels of C-peptide and they were more often treated with insulin. 
Genotype and risk of LADA and Type 2 diabetes  
As expected, HLA high-risk genotypes were associated with LADA in both cohorts, RRpooled 
2.74 (95% CI 2.23-3.36). TCF7L2 was associated with LADA only in ESTRID (ESTRID vs. 
HUNT: RR 1.30 (95% CI 1.03-1.64) vs. 1.00 (95% CI 0.71-1.41); RRpooled 1.20 (95% CI 
0.99-1.45), while FTO was significantly associated with LADA only in HUNT (RR 1.11 
(95% CI 0.86-1.42) vs. RR 1.65 (95% CI 1.10-2.46); RRpooled 1.24 (95% CI 1.00-1.53) 
(Figure 1). Stratifying the analyses by median GADA level indicated that the association 
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with HLA was stronger for LADAhigh than for LADAlow while the association with TCF7L2 
and FTO was restricted to LADAlow (Supplemental figure 1) (27). When restricting the 
analysis to LADAlow, the results regarding TCF7L2 and FTO were more consistent across 
studies (Supplemental figure 1). Using a stricter LADA definition in HUNT, i.e. no insulin 
treatment, did not change the results (Supplemental table 1) (27). The highest risk of LADA 
was seen in those homozygous for the HLA DR4 allele (OR 13.73, 95% CI 9.35-20.18) out 
of whom 91% also had the DQ8 risk genotype (Supplemental figure 2 and Supplemental 
table 2 [ESTRID]) (27). In both studies, type 2 diabetes was associated with TCF7L2 and 
FTO but not with HLA (Figure 1).   
Gene-overweight interaction and risk of LADA 
Individuals with a combination of overweight (BMI ≥ 25 kg/m2) and HLA high-risk 
genotypes had almost 8-fold increased risk of LADA (RRpooled 7.59, 95% CI 5.27-10.93) 
(Table 2) and a combination of DR4/4 and overweight appeared most detrimental (RR
 
26.76, 
95% CI 15.42-46.43 [ESTRID]) (Figure 2 and Supplemental table 3) (27). In comparison, 
the combination of overweight with TCF7L2 and FTO risk alleles yielded an RRpooled of 2.65 
(95% CI 1.97-3.56) and 2.21 (95% CI 1.60-3.07), respectively.  
Moreover, there was significant interaction between overweight and all genotypes; 
APpooled was 0.29, 95% CI 0.10-0.47 (HLA); 0.31, 95% CI 0.09-0.52 (TCF7L2), and 0.38, 
95% CI 0.15-0.61 (FTO) suggesting that around 29-38% of the LADA cases exposed to both 
risk factors might be prevented by maintaining a normal weight (Table 2). Overall, these 
results were consistent across cohorts (Table 2). The interaction between overweight and 
HLA was primarily observed for LADAhigh and the interaction with TCF7L2 primarily with 
LADAlow (Supplemental table 4) (27). 
The combination of obesity (BMI ≥ 30 kg/m2) and risk genotypes yielded an even higher 
risk of diabetes (Supplemental table 5) (27), notably individuals with obesity and HLA risk 
genotypes had an RRpooled of LADA 9.20 (6.53-12.96), with APpooled estimated at 0.41 (0.21-
0.62).  
Gene-overweight interaction and risk of type 2 diabetes  
Interaction was observed between overweight and the TCF7L2 risk allele; the joint exposure 
increased the risk ten-fold (RRpooled 10.14, 95% CI 8.42-12.22) which corresponded to an 
APpooled of 0.26, 95% CI 0.19-0.33 (Table 3). No interaction was observed between 
overweight (Table 3) and either FTO or HLA. Findings were similar in obese vs. non obese 
individuals (Supplemental table 5) (27). 
Discussion 
We found a striking interaction between overweight/obesity and high-risk HLA genotypes in 
relation to the risk of LADA. Furthermore, the risk conferred by excess weight was especially 
high in those with the DR4/4 genotype. We also present novel results suggesting that excess 
weight interacts with TCF7L2 and FTO risk alleles in the promotion of LADA but only with 
TCF7L2 in promoting type 2 diabetes.  
We confirm that HLA is strongly associated with the risk of LADA (6-8). The association 
with TCF7L2 and FTO was much weaker and primarily seen for LADA with low GADA 
levels. Previous studies on LADA and FTO (12,13,28) and TCF7L2 (9-13,29) have yielded 
inconsistent results, including a recent GWAS which did not find an association with either 
genotype (8). The lack of association may reflect limited power, especially in the GWAS 
where the nominal p-value was significant but not at the genome-wide significance level. It 
may also reflect the heterogeneity of LADA as shown here and in previous analyses of 
TCF7L2 in relation with high and low GADA levels (11,12,29). With regard to type 2 
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diabetes, we confirm earlier studies indicating that the risk is associated with TCF7L2 and 
FTO but not HLA (5).  
The highest risk of LADA was seen in individuals with a combination of 
overweight/obesity and high-risk HLA genotypes. The HLA-complex is responsible for 
regulating the immune system and polymorphisms in this region are associated with 
development of insulin deficiency, presumably through autoimmune destruction of the 
pancreatic beta-cells (30). The influence of excess weight on LADA risk may be mediated by 
insulin resistance (4). One can hypothesize that when insulin resistance increases the need of 
insulin and the beta-cells fail to compensate for this need due to genetically determined 
insulin deficiency, the risk of diabetes escalates. This fits with the accelerator hypothesis 
which proposes that both type 2 diabetes and autoimmune diabetes are the result of 
disequilibrium between insulin sensitivity and insulin production (31). Another possibility is 
that high BMI promotes autoimmunity and adds to the genetically induced autoimmune 
reactivity. In support of that suggestion, Rolandsson et al found a positive association 
between BMI and GADA levels in a sample of non-diabetic individuals  (32). Moreover, 
higher BMI has been associated with higher expression of the GAD2 gene in beta-cells of 
non-diabetic subjects (33). In apparent contrast to these observations, several studies have 
shown an inverse association between BMI and GADA levels among LADA patients 
(4,5,34); although one study showed that antibodies to a fragment of IA2 (protein tyrosine 
phosphatase islet antigen-2
 (256-760)) was associated with obesity in LADA patients (35). 
However, this inverse association between two risk factors of LADA may reflect collider bias 
due to restricting the study sample to patients with LADA (36).   
The strongest interaction was observed in overweight individuals with the DR4/DR4 
genotype, which to our knowledge has not been investigated previously. In this context it is 
noteworthy that significant interaction between HLA-DRB1*15 and adolescent obesity is 
observed in relation to the risk of multiple sclerosis (37). Further support is found in studies 
of type 1 diabetes in children; a Swedish case-only study (38) report a significant synergistic 
effect between overweight and HLA high-risk genotypes and results from the TEDDY study 
suggests that the effect of HLA-DQ2/2 genotype on diabetes risk could be mediated by 
obesity (39).  
We also observed interaction between overweight and TCF7L2 in relation to both LADA 
and type 2 diabetes. The TCF7L2 locus is involved in the function of beta-cells and the 
rs7903146 risk variant is associated with increased gene expression in islets and reduced 
insulin secretion in a non-autoimmune fashion (40). Consequently, the excess risk seen in 
those exposed to both risk factors could be explained by failure of the beta-cells in carriers of 
TCF7L2 to compensate for obesity induced insulin resistance in a similar way as described 
above. We did not find any previous reports of the combined effect of high BMI and TCF7L2 
on neither LADA nor type 2 diabetes, but if we recalculate the numbers presented in table 1 
in the Hungarian LADA study by Lukacs et al. (10) there is no interaction and in contrast to 
our findings, no overall association between overweight and LADA is seen. These 
inconsistences may relate to differences in the populations or in study design, e.g. the 
Hungarian study was based on prevalent cases that were both younger and leaner than those 
included in this study. However, in keeping with our results are data from Cauchi et al. (41); 
when we recalculate the numbers in table 1 the results indicate additive interaction between 
obesity and the TCF7L2 TT/TC genotype with AP estimated to 18.4%.  
Similarly, a significant interaction between overweight and FTO was seen in LADA. The 
FTO gene is suggested to impact energy homeostasis control, with increased hunger and 
increased body fat in those with the risk variant (42). It has also been suggested that the 
impact of FTO is modulated by diet and eating behavior (42). A mechanistic explanation may 
be that environmental risk factors exaggerate the risk of overweight and subsequent insulin 
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resistance and diabetes in genetically susceptible individuals. Clearly these findings need 
confirmation, especially since we did not find any interaction for type 2 diabetes. 
The strengths of this study include the possibility to replicate our findings in two large 
independent populations, the enrollment of incident cases as well as the detailed information 
on potential confounders. The self-reported information on weight and height in ESTRID is a 
drawback that may have led to an underestimation of the association between BMI and 
LADA/type 2 diabetes (43). We were able to validate the self-reports of the patients and 
found the correlation with information from their medical records to be high. In HUNT we 
had the advantage of using anthropometric measurements. In ESTRID, cases were matched to 
controls from another study population. The validity of this approach is supported by the fact 
that the results regarding LADA/type 2 diabetes and BMI was similar to those of a previous 
report where we used the controls recruited within ESTRID, for whom we did not have 
genetic information (4). Related to control sampling is also the fact that different assays were 
used for genotyping the cases and controls, thus a possible batch effect could have impacted 
these results. Such effect is most likely minor since our findings are in agreement with what 
has been reported previously (5,10-12). With regard to diagnostic criteria, LADA was 
distinguished from type 2 diabetes by means of only one autoantibody. This implies that 
some patients with autoimmune diabetes may have been included in the type 2 diabetes 
group. The proportion is likely to be small since GADA has been shown to be the most 
common autoantibody in LADA; 90% of LADA patients in the Action LADA study and 99% 
in a sub-study of HUNT were positive for GADA(44), (45). Also, some LADA patients may 
have converted to seronegative after diagnosis in the HUNT Study, in which GADA were 
assessed several years after diagnosis(45). Importantly, the lack of association between HLA 
risk genotypes and type 2 diabetes indicates that the proportion of misclassified autoimmune 
diabetes patients was small. In addition, the risk associated with TCF7L2 was similar in those 
with low and high GADA levels in ESTRID and in a previous study from Finland11, although 
not in HUNT. Moreover, even though specificity of the GADA assay was high, it is possible 
that some type 2 diabetes patients were misclassified as having LADA. Notably we observed 
a strong association with HLA high-risk genotypes and LADA, including LADAlow, which 
indicates that we did manage to isolate an autoimmune patient group. The criteria used to 
distinguish between LADA and type 1 diabetes with adult onset differed across studies; we 
used C-peptide levels in ESTRID and lack of insulin treatment within the first year following 
diagnosis in HUNT (sensitivity analysis). Although the LADA population in HUNT by 
definition is enriched by type 1 diabetes subjects, their proportion of GADA positive patients 
in that age-group is likely to be small, which is supported by the fact that they tended to have 
a more type 2-like phenotype than the LADA patients in ESTRID with higher HOMA-B 
levels, higher mean BMI and a stronger association with the FTO risk variant. This points at 
the heterogeneous nature of LADA (46). In this context it is important to note that results 
regarding interaction between BMI and HLA in relation to LADA risk were consistent across 
studies. Insulin treatment was more common in ESTRID than in HUNT but this most likely 
reflects differences in treatment strategies than in phenotype; although debated (46), early 
intervention with insulin has been suggested to preserve endogenous insulin secretion in 
LADA (18) and this could explain the frequent insulin treatment of the Swedish patients. 
With respect to generalizability, this report is based on Scandinavia populations; hence 
replications in other populations with different ethnic and genetic background are warranted 
in order to generalize the findings.  
Conclusions  
In conclusion, our study suggests that overweight strongly interacts with HLA high-risk 
genotypes but also with risk variants of TCF7L2 and FTO in LADA, indicating that excessive 
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weight is a particularly strong risk factor for LADA in individuals with genetic susceptibility. 
As such, our data put forward that lifestyle modification to maintain a healthy weight may be 
particularly important for prevention of LADA among people with HLA risk alleles.  
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Figure 1. Relative risks with 95% confidence intervals of LADA and type 2 diabetes by 
genotypes of HLA (high-risk vs. low/intermediate risk), TCF7L2 (TT/TC vs. CC), and FTO 
(AA/AT vs. TT). 
Figure 2. Relative risks with 95% confidence intervals of LADA in relation to different 
combinations of BMI and genotypes of HLA DRB1 in the ESTRID study. *Reference is 
normal weight individuals with low/intermediate risk HLA genotypes. Adjusted for age and 
gender. 
Table 1. Characteristics of study participants 
 ESTRID    HUNT    
 Controls LADA Type 2 
diabetes 
pa No 
diabetes 
LADA Type 2 diabetes pa 
No. of individuals 2,656 394 1,290  46,567 131 1,901  
Men, % 27.6 53.0 60.1 0.0132 46.7 48.9 52.8 0.3864 
Age at diagnosisb, years, mean 
(SD) 
56.6 
(9.4) 58.6 (12.3) 63.2 (10.3) <0.0001– 59.5 (11.2) 60.7 (10.9) 0.1914 
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 ESTRID    HUNT    
 Controls LADA Type 2 
diabetes 
pa No 
diabetes 
LADA Type 2 diabetes pa 
Age, years, at baseline (HUNT), 
mean (SD) 
– – – 
– 
48.9 
(15.8) 54.0 (11.4) 54.6 (11.0) 0.5418 
BMI (kg/m2), mean (SD) 
25.5 
(4.1) 27.9 (5.2) 31.2 (5.3) <0.000125.9 (3.8) 29.1 (4.8) 29.8 (4.5) 0.1066 
Overweight, % 47.5 70.1 93.4 <0.000156.2 82.4 88.3 0.0456 
With insulin treatment, % – 47.4 5.8 <0.0001– 45.8 15.0 <0.0001 
GADA (IU/ml), median (IQR) – 206 (27-250) – – – 151 (59-613) – – 
C-peptide (nmol/l), median 
(IQR)c – 
0.66 (0.42-
1.10) 
1.20 (0.95-
1.60) <0.0001– 
0.53 (0.18-
0.91) 
0.86 (0.60-
1.20) <0.0001 
HOMA-B, median (IQR)c – 
34.2 (13.3-
65.1) 
68.1 (42.5-
92.8) <0.0001– 
58.5 (36.6-
81.9) 
65.3 (43.8-
92.9) 0.2696 
HOMA-IR, median (IQR)c – 
2.70 (1.80-
4.40) 
3.60 (2.70-
4.80) <0.0001– 
2.05 (1.10-
2.70) 
2.20 (1.60-
3.10) 0.0547 
High-risk HLA, % 33.0 61.2 31.4 <0.000142.5 60.3 40.7 <0.0001 
TCF7L2-rs7903146, % d 45.8 51.8 52.1 0.7795 44.2 44.3 54.9 0.0186 
FTO-rs9939609, % e 64.33 66.3 67.5 0.5156 65.9 76.3 69.2 0.0847 
a) P for difference between LADA and type 2 diabetes. b) Age at inclusion for control participants in ESTRID. 
c) Clinical information was available for 100% of the patients in ESTRID and 70% of patients in HUNT 
(LADA n=105, type 2 diabetes n=1,316). d) Proportion with the TT/TC genotype. e) Proportion with the 
AA/AT genotype. HLA high-risk: DR4/4, DR3/3, DR3/4, DR3/4-DQ8, DR4/4-DQ8 or DR4/X-DQ8. 
Table 2. Relative risks (RR) and attributable proportion due to interaction (AP) with 95% 
Confidence Intervals (CI) in relation to LADA for different combinations of BMI and 
genotypes of HLA, TCF7L2 and FTO. 
 
 ESTRID HUNT Pooled 
 
 No. 
cases 
No. controls 
RR (95% CI) 
No. 
cases 
Person-
years RR (95% CI) RR (95% CI) 
BMI 
≥25 
HLA high-risk       
- - 42 637 1 (Reference) 8 251,825 1 (Reference) 1 (Reference) 
+ - 111 587 2.57 (1.69-3.92) 44 258,428 3.86 (1.81-8.26) 2.83 (1.96-4.09) 
- + 76 325 3.84 (2.43-6.05) 15 186,239 2.55 (1.08-6.01) 3.51 (2.35-5.25) 
+ + 165 277 7.56 (4.97-11.50) 64 189,628 7.67 (3.65-16.09) 7.59 (5.27-10.93) 
 
AP 
(95% 
CI) 
  0.28 ( 0.05-0.52)   0.29 ( 0.00-0.59) 0.29 (0.10-0.47) 
BMI 
≥25 
TCF7L2 TT/TC       
- - 58 756 1 (Reference) 18 241,094 1 (Reference) 1 (Reference) 
+ - 121 672 1.91 (1.34-2.73) 55 251,403 2.10 (1.22-3.61) 1.97 (1.46-2.65)  
- + 55 631 1.19 (0.79-1.80) 5 196,969 0.34 (0.13-0.91) 0.43 (0.36-0.51)  
+ + 137 576 2.67 (1.88-3.79) 53 196,654 2.60 (1.51-4.47) 2.65 (1.97-3.56)  
 AP 
(95% 
CI) 
  0.21 ( -0.07-0.49)   0.45 ( 0.11-0.78) 0.31 (0.09-0.52) 
BMI 
≥25 
FTO AA/AT       
- - 47 475 1 (Reference) 9 156,631 1 (Reference) 1 (Reference) 
+ - 78 387 1.61 (1.06-2.44) 22 144,128 1.91 (0.87-4.16) 1.67 (1.16-2.42)  
- + 66 794 0.80 (0.53-1.22) 14 281,432 0.87 (0.38-2.02) 0.81 (0.56-1.18)  
+ + 180 761 1.93 (1.33-2.79) 86 303,929 3.58 (1.79-7.15) 2.21 (1.60-3.07)  
 
AP 
(95% 
CI) 
  0.27 ( -0.06-0.59)   0.50 ( 0.17-0.83) 0.38 (0.15-0.61) 
Adjusted for age, gender, smoking and physical activity. HLA high-risk: DR4/4, DR3/3, DR3/4, DR3/4-DQ8, 
DR4/4-DQ8 or DR4/X-DQ8. 
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Table 3. Relative risks (RR) and attributable proportion due to interaction (AP) with 95% 
confidence intervals (CI) in relation to type 2 diabetes for different combinations of BMI and 
genotypes of HLA, TCF7L2 and FTO.  
 
 ESTRID HUNT Pooled 
  
No. 
cases 
No. 
controls RR (95% CI) 
No. 
cases 
Person-
years RR (95% CI) RR (95% CI) 
BMI 
≥25 
HLA high-
risk        
- - 57 637 1 (Reference) 124 251,825 1 (Reference) 1 (Reference) 
+ - 825 587 16.49 (11.42-23.81) 1004 258,428 5.61 (4.65-6.77) 7.01 (5.93-8.29) 
- + 27 325 1.48 (0.85-2.58) 98 186,239 1.06 (0.82-1.39) 1.13 (0.89-1.43) 
+ + 376 277 15.51 (10.50-22.90) 675 189,628 5.16 (4.25-6.26) 6.42 (5.39-7.63) 
 
AP (95% CI)   -0.09 ( -0.34-0.15 )   
-0.10 (-0.22-
0.02) 
-0.10 (-0.21-
0.01) 
BMI 
≥25 
TCF7L2 
TT/TC        
- - 40 756 1 (Reference) 95 241,094 1 (Reference) 1 (Reference) 
+ - 556 672 14.73 (10.01-21.68) 763 251,403 5.46 (4.40-6.77) 6.91 (5.72-8.34) 
- + 43 631 1.64 (1.00-2.70) 127 196,969 1.63 (1.25-2.12) 1.63 (1.29-2.06) 
+ + 606 576 18.78 (12.74-27.69) 916 196,654 
8.43 (6.82-
10.43) 
10.14 (8.42-
12.22) 
 
AP (95% CI)   0.18 ( 0.03-0.33 )   0.28 (0.20-0.36) 0.26 (0.19-0.33) 
BMI 
≥25 
FTO  
AA/AT        
- - 30 475 1 (Reference) 76 156,631 1 (Reference) 1 (Reference) 
+ - 375 387 12.52 (8.01-19.58) 510 144,128 5.23 (4.10-6.66) 6.38 (5.15-7.90) 
- + 53 794 1.07 (0.64-1.79) 146 281,432 1.08 (0.82-1.43) 1.08 (0.84-1.38) 
+ + 787 761 14.23 (9.24-21.92) 1169 303,929 5.72 (4.53-7.22) 7.13 (5.77-8.82) 
 
AP (95% CI)   0.12 ( -0.06-0.29 )   0.07 (-0.04-0.18) 0.08 (-0.01-0.18) 
Adjusted for age, gender, smoking and physical activity. HLA high-risk: DR4/4, DR3/3, DR3/4, DR3/4-DQ8, 
DR4/4-DQ8 or DR4/X-DQ8. 
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